Vital Signs - Will Drug and Gene Therapy Eradicate Angioplasty?


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on October 23, 2006, provides a strategic overview and discussion of the potential impact of drug and gene therapy on the amount of angioplasty procedures in clinical practice. Additionally, an emerging company profile is provided for Foxhollow Technologies Inc., a leader in the development and manufacturing of plaque excision devices for PAD. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of October 9 - October 13, 2006.

Table of Contents

Vital Signs - Will Drug and Gene Therapy Eradicate Angioplasty?Vital Signs: 23 October 2006This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.